Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high39.50 10/10/17
52 week low19.50 12/12/16
52 week change 9.13 (42.20%)
4 week volume4,474,515 23/10/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Allergy Therapeutics to Present at Jefferies 2017

RNS Number: 2495W Allergy Therapeutics PLC 13 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics to Present at Jefferies 2017 London Healthcare Conference 13 November 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces th...

Director/PDMR Shareholding

RNS Number: 8138V Allergy Therapeutics PLC 07 November 2017 The announcement released by Allergy Therapeutics plcentitled "Director/ PDMR Shareholding" on 7 November 2017 at 11:54 incorrectly stated the exercise price as 0.0001 per share. The correct exercise price is 0.001. All other figures remain unchanged. The correct figure is included in the reissued ann...

Director/PDMR Shareholding

RNS Number: 8006V Allergy Therapeutics PLC 07 November 2017 07 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Grant of Options under Long Term Incentive Plan Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that certain performance c...

Publication of Annual Report and notice of AGM

RNS Number: 1267U Allergy Therapeutics PLC 19 October 2017 19 October 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") ANNUAL FINANCIAL REPORT 2017 AND NOTICE OF 2017 ANNUAL GENERAL MEETING Allergy Therapeutics Plc has today published the following documents: Annual Report for the year ended 30 June 201...

Allergy Therapeutics starts dosing for grass pollen trial

Allergy Therapeutics has started its G205 phase II study designed to evaluate the dose-response and safety of its ultra-short c...

Commencement of dosing in PQ Grass Phase II Trial

RNS Number: 0102U Allergy Therapeutics PLC 19 October 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Commencement of dosing in PQ Grass Phase II Trial 19 October 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces that dosing has commenced i...

Holding(s) in Company

RNS Number: 4959T Allergy Therapeutics PLC 12 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Allergy The...

Director Deals - Allergy Therapeutics PLC (AGY)

Dr Tunde Otulana, Non Executive Director, bought 25,000 shares in the company on the 11th October 2017 at a price of 38.4...

Fundamental DataMore

EPS-0.42
Dividend yield0 %

Latest discussion posts More

  • Peanut Allergies

    Interesting article on p8 of Daily Telegraph today. Year long trial using patches (not injections like AGY). 50% of those wearing the strongest dosage patches experienced a ...
    15-Nov-2017
    jres
  • Re: Excellent Volume

    Harman although I like the sound of Hardpan Research. I could have done with some of that many times in investments made!!
    10-Oct-2017
    Chicken Lips
  • Excellent Volume

    Excellent volume today. The hardpan research or maybe AGY is beginning to be noticed with its excellent product and product pipeline. CL
    10-Oct-2017
    Chicken Lips

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..
LLOYDS GRP.26%
BP21%
SIRIUS MINERALS18%
VODAFONE GRP.16%
BARCLAYS15%

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account